Novel ligand for for quantification of synaptic density in brain (SV2A) now produced by PharmaSynth AS

PharmaSynth AS is now producing BF3-Dm-UCB-J, a precursor for[11C]UCB-J, a selective radioligand for synaptic vesicle glycoprotein 2A (SV2A), as well as its reference standard.

For more information regarding the ligand activity and findings, please consult the publications:

Imaging synaptic density in the living human brain

Finnema, S. J. et.al., Sci Transl Med. 2016, vol 8, issue 348.

Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein
2A in the Brain

Nabulsi, N. B. et al., J Nucl Med. 2016, 57, 777-784.

Corresponding products in our portfolio:


Reference standard



For further information regarding technical specifications please contact Jukka Hiltunen at jukka@pharmasynth.ee or our chief chemist, Olavi Loog at olavi@pharmasynth.ee or by using the contact form on our webpage.